Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher
Benzinga (Wed, 8-May 1:49 PM ET)
Benzinga (Wed, 8-May 1:38 PM ET)
Teva hits a five-year high on schizophrenia trial win, Q1 beat
Seeking Alpha News (Wed, 8-May 10:13 AM ET)
Teva, Medincell succeed in late-stage trial for injectable schizophrenia therapy
Seeking Alpha News (Wed, 8-May 7:40 AM ET)
Benzinga (Wed, 8-May 7:13 AM ET)
Options Volatility and Implied Earnings Moves Today, May 08, 2024
TipRanks (Wed, 8-May 7:05 AM ET)
Teva Pharmaceutical reports mixed Q1 results; reaffirms FY24 outlook
Seeking Alpha News (Wed, 8-May 7:03 AM ET)
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
Business Wire (Wed, 8-May 7:00 AM ET)
Business Wire (Wed, 8-May 6:30 AM ET)
Investor Sentiment Falls Further, Dow Gains For Fifth Session
Benzinga (Wed, 8-May 3:49 AM ET)
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Teva Pharmaceutical Industries Limited American Depositary Shares trades on the NYSE stock market under the symbol TEVA.
As of May 8, 2024, TEVA stock price climbed to $15.74 with 35,210,337 million shares trading.
TEVA has a beta of 0.64, meaning it tends to be less sensitive to market movements. TEVA has a correlation of 0.05 to the broad based SPY ETF.
TEVA has a market cap of $17.83 billion. This is considered a Large Cap stock.
Last quarter Teva Pharmaceutical Industries Limited American Depositary Shares reported $4 billion in Revenue and $1.00 earnings per share. This beat revenue expectation by $447 million and exceeded earnings estimates by $.23.
In the last 3 years, TEVA stock traded as high as $16.13 and as low as $6.78.
The top ETF exchange traded funds that TEVA belongs to (by Net Assets): IEFA, EFA, EFV, IXUS, PPH.
TEVA has outperformed the market in the last year with a price return of +79.5% while the SPY ETF gained +27.0%. TEVA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +29.7% and +21.0%, respectively, while the SPY returned +4.2% and +2.3%, respectively.
TEVA support price is $13.67 and resistance is $14.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TEVA stock will trade within this expected range on the day.